X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs MYLAN (US) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   MYLAN
EQUITY SHARE DATA
    CIPLA
Mar-17
MYLAN
Dec-14
CIPLA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6224,053-   
Low Rs4582,856-   
Sales per share (Unadj.) Rs181.91,387.6-  
Earnings per share (Unadj.) Rs12.9167.2-  
Cash flow per share (Unadj.) Rs29.3269.1-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.7689.8-  
Shares outstanding (eoy) m804.51378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x3.02.5 119.3%   
Avg P/E ratio x42.020.7 203.0%  
P/CF ratio (eoy) x18.412.8 143.5%  
Price / Book Value ratio x3.55.0 69.3%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5161,307,233 33.2%   
No. of employees `00023.025.0 92.2%   
Total wages/salary Rs m26,3380-   
Avg. sales/employee Rs Th6,349.121,001.5 30.2%   
Avg. wages/employee Rs Th1,143.00-   
Avg. net profit/employee Rs Th449.32,530.0 17.8%   
INCOME DATA
Net Sales Rs m146,302525,037 27.9%  
Other income Rs m2,287-3,060 -74.7%   
Total revenues Rs m148,589521,977 28.5%   
Gross profit Rs m24,758130,579 19.0%  
Depreciation Rs m13,22938,562 34.3%   
Interest Rs m1,59422,647 7.0%   
Profit before tax Rs m12,22266,310 18.4%   
Minority Interest Rs m0-272 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7982,788 64.5%   
Profit after tax Rs m10,35463,249 16.4%  
Gross profit margin %16.924.9 68.0%  
Effective tax rate %14.74.2 349.8%   
Net profit margin %7.112.0 58.7%  
BALANCE SHEET DATA
Current assets Rs m87,370461,577 18.9%   
Current liabilities Rs m33,081360,861 9.2%   
Net working cap to sales %37.119.2 193.4%  
Current ratio x2.61.3 206.5%  
Inventory Days Days8778 111.4%  
Debtors Days Days62107 58.1%  
Net fixed assets Rs m111,567121,466 91.9%   
Share capital Rs m1,60918,567 8.7%   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,254260,995 48.0%   
Long term debt Rs m36,454389,901 9.3%   
Total assets Rs m209,5321,051,265 19.9%  
Interest coverage x8.73.9 220.7%   
Debt to equity ratio x0.31.5 19.5%  
Sales to assets ratio x0.70.5 139.8%   
Return on assets %5.78.2 69.8%  
Return on equity %8.324.2 34.1%  
Return on capital %8.513.6 62.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,82469,017 34.5%  
From Investments Rs m-13,127-54,428 24.1%  
From Financial Activity Rs m-13,239-18,186 72.8%  
Net Cashflow Rs m-2,478-3,598 68.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare CIPLA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare CIPLA With: AJANTA PHARMA  SUVEN LIFE  PANACEA BIOTECH  VENUS REMEDIES  AUROBINDO PHARMA  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 19, 2018 03:37 PM

TRACK CIPLA

CIPLA - ABBOTT INDIA COMPARISON

COMPARE CIPLA WITH

MARKET STATS